- ImmunoGen press release (NASDAQ:IMGN): Q2 GAAP EPS of -$0.24 misses by $0.03.
- Revenue of $14.2M (-16.2% Y/Y) misses by $1.98M.
- ImmunoGen had $373.9 million in cash and cash equivalents as of June 30, 2022, compared with $478.8 million as of December 31, 2021.
FINANCIAL GUIDANCEImmunoGen’s financial guidance for 2022 remains unchanged; the Company continues to expect:
- revenues between $75 million and $85 million vs consensus of $84.68M;
- operating expenses between $285 million and $295 million; and
- cash and cash equivalents at December 31, 2022 to be between $245 million and $255 million.
- Shares +4.76% PM.